Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells

Cancer Research

Volumn 67, Issue 17, 2007, Pages 8358-8367

  Napoletano, Chiara ^a   Rughetti, Aurelia ^a   Agervig Tarp, Mads P ^c   Coleman, Julia ^e   Bennett, Eric P ^d   Picco, Gianfranco ^e   Sale, Patrizio ^a,b   Denda Nagai, Kaori ^f   Irimura, Tatsuro ^f   Mandel, Ulla ^d   Clausen, Henrik ^c   Frati, Luigi ^a   Taylor Papadimitriou, Joyce ^e   Burchell, Joy ^e   Nuti, Marianna ^a,g  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e GUY S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF TOKYO   (Japan)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN DERIVATIVE; GLYCOPEPTIDE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; LECTIN; MACROPHAGE GALACTOSE TYPE C TYPE LECTIN; MACROPHAGE GALACTOSE TYPE C TYPE LECTIN RECEPTOR; MUCIN 1; N ACETYLGALACTOSAMINE; RECEPTOR; RECOMBINANT PROTEIN; TN ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CELL FRACTIONATION; CELL STRAIN K 562; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HUMAN; HUMAN CELL; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TANDEM REPEAT;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-15-3 ANTIGEN; CELLS, CULTURED; DENDRITIC CELLS; ENDOCYTOSIS; GLYCOSYLATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; K562 CELLS; LECTINS, C-TYPE; PROTEIN ISOFORMS; RECOMBINANT PROTEINS;

EID: 34548593215     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1035     Document Type: Article

References (49)

1. Dube DH, Bertozzi CR. Glycans in cancer and inflammation - potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005;4:477-88.
2. Guillot J, Guerry M, Konska G, Caldefie-Chezet F, De Latour M, Penault-Llorca F. Modification of glycoconjugates during the carcinogenesis: the case of mammary carcinomas. Bull Cancer 2004;91:141-58.
3. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 2001;491:369-402.
4. Vlad AM, Finn OJ. Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Dis 2004;20:73-9.
5. Gendler SJ, Spicer AP, Lalani EN, et al. Structure and biology of a carcinoma-associated mucin, MUC1. Am Rev Respir Dis 1991;144:S42-7.
6. Hanisch FG. O-Glycosylation of the mucin type. Biol Chem 2001;382:143-9.
7. Taylor-Papadimitriou J, Burchell JM, Plunkett T, et al. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002;7:209-21.
8. Burchell JM, Mungul A, Taylor-Papadimitriou J. O-Linked glycosylation in the mammary gland: changes that occur during malignancy. J Mammary Gland Biol Neoplasia 2001;6:355-64.
9. Acres B, Apostolopoulos V, Balloul JM, et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 2000;48:588-94.
10. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96:3102-8.
11. Apostolopoulos V, Pietersz GA, Tsibanis A, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 2006;8:R27.
12. Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005;54:254-64.
13. Sorensen AL, Reis CA, Tarp MA, et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006;16:96-107.
14. Kagan E, Ragupathi G, Yi SS, et al. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn. Cancer Immunol Immunother 2005;54:424-30.
15. Nath D, Hartnell A, Happerfield L, et al. Macrophage-tumor cell interactions: indentification of MUC1 on breast cancer cells as a potential counter receptor for the macrophage-restricted receptor, sialoadhesin. Immunology 1999;98:231-19.
16. Rughetti A, Biffoni M, Pierelli L, et al. Regulated expression of MUC1 epithelial antigen in erythropoiesis. Br J Haematol 2003;120:344-52.
17. Rughetti A, Pellicciotta I, Biffoni M, et al. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol 2005;174:7764-72.
18. Cambi A, Figdor CG. Dual function of C-type lectin-like receptors in the immune system. Curr Opin Cell Biol 2003;15:539-46.
19. Cambi A, Koopman M, Figdor CG. How C-type lectins detect pathogens. Cell Microbiol 2005;7:481-8.
20. Geijtenbeek TB, van Vliet SJ, Engering A, 't Hart BA, van Kooyk Y. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 2004;22:33-54.
21. van Gisbergen KP, Aarnoudse CA, Meijer GA, Geijtenbeek TB, van Kooyk Y. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin. Cancer Res 2005;65:5935-44.
22. Suzuki N, Yamamoto K, Toyoshima S, Osawa T, Irimura T. Molecular cloning and expression of cDNA encoding human macrophage C-type lectin. Its unique carbohydrate binding specificity for Tn antigen. J Immunol 1996;156:128-35.
23. Fontenot JD, Finn OJ, Dales N, Andrews PC, Montelaro RC. Synthesis of large multideterminant peptide immunogens using a poly-proline β-turn helix motif. Pept Res 1993;6:330-6.
24. Bennett EP, Hassan H, Mandel U, et al. Cloning of a human UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyl transferase that complements other GalNAc-transferases in complete O-glycosylation of the MUC1 tandem repeat. J Biol Chem 1998;273:30472-81.
25. Schwientek T, Bennett EP, F lores C, et al. Functional conservation of subfamilies of putative UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferases in Drosophila, Caenorhabditis elegans, and mammals. One subfamily composed of l(2)35Aa is essential in Drosophila. J Biol Chem 2002;277:22623-38.
26. Ragupathi G, Cappello S, Yi SS, et al. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Vaccine 2002;20:1030-8.
27. Wandall HH, Irazoqui F, Tarp MA, et al. The lectin domains of polypeptide GalNAc-transferases exhibit carbohydrate-binding specificity for GalNAc: lectin binding to GalNAc-glycopeptide substrates is required for high density GalNAc-O-glycosylation. Glycobiology 2007;17:374-87.
28. Reis CA, Sorensen T, Mandel U, et al. Development and characterization of an antibody directed to an α-N-acetyl-D-galactosamine glycosylated MUC2 peptide. Glycoconj J 1998;15:51-62.
29. Kingsley DM, Kozarsky KF, Hobbie L, Krieger M. Reversible defects in O-linked glycosylation and LDL receptor expression in a UDP-Gal/UDP-GalNAc 4-epimerase deficient mutant. Cell 1986;44:749-59.
30. Higashi N, Fujioka K, Denda-Nagai K, et al. The macrophage C-type lectin specific for galactose/N-acetylgalactosamine is an endocytic receptor expressed on monocyte-derived immature dendritic cells. J Biol Chem 2002;277:20686-93.
31. Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T. Recent developments in therapeutic cancer vaccines. Nat Clin Pract Oncol 2005;2:108-13.
32. Laheru DA, Pardoll DM, Jaffee EM. Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. Mol Cancer Ther 2005;4:1645-52.
33. Graham RA, Burchell JM, Taylor-Papadimitriou J, et al. The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Cancer Immunol Immunother 1996;42:71-80.
34. van der Bruggen P, Van den Eynde BJ. Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 2006;18:98-104.
35. Carlos CA, Dong HF, Howard OMZ, Oppenheim JJ, Hanish FG, Finn OJ. Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol 2005;175:1628-35.
36. Higashi N, Morikawa A, Fujioka K, et al. Human macrophage lectin specific for galactose/N-acetylgalactosamine is a marker for cells at an intermediate stage in their differentiation from monocytes into macrophages. Int Immunol 2002;14:545-54.
37. Denda-Nagai K, Kubota N, Tsuiji M, Kamata M, Irimura T. Macrophage C-type lectin on bone marrow-derived immature dendritic cells is involved in the internalization of glycosylated antigens. Glycobiology 2002;12:443-50.
38. van Vliet SJ, van Liempt E, Saeland E, et al. Carbohydrate profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells. Int Immunol 2005;17:661-9.
39. van Liempt E, van Vliet SJ, Engering A, et al. Schistosoma mansoni soluble egg antigens are internalized by human dendritic cells through multiple C-type lectins and suppress TLR-induced dendritic cell activation. Mol Immunol 2007;44:2605-15.
40. Lo-Man R, Vichier-Guerre S, Bay S, Deriaud E, Cantacuzene D, Leclerc C. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope. J Immunol 2001;166:2849-54.
41. Saeland E, van Vliet SJ, Backstrom M, et al. The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol Immunother 2007;56:1225-36.
42. Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 2000;165:3730-41.
43. Hanisch FG, Schwientek T, Von Bergwelt-Baildon MS, Schultze JL, Finn O. O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur J Immunol 2003;33:3242-54.
44. Hiltbold EM, Alter MD, Ciborowski P, Finn OJ. Presentation of MUC1 tumor antigen by class I HLA and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell Immunol 1999;194:143-9.
45. Dzhambazov B, Holmdahl M, Yamada H, et al. The major T cell epitope on type II collagen is glycosylated in normal cartilage but modified by arthritis in both rats and humans. Eur J Immunol 2005;35:357-66.
46. Dudler T, Machado DC, Kolbe L, et al. A link between catalytic activity, IgE-independent mast cell activation, and allergenicity of bee venom phospholipase A2. J Immunol 1995;155:2605-13.
47. Xu Y, Gendler SJ, Franco A. Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J Exp Med 2004;199:707-16.
48. Haurum JS, Arsequell G, Lellouch AC, et al. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med 1994;180:739-44.
49. Stepensky D, Tzehoval E, Vadai E, Eisenbach L. O-Glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin Exp Immunol 2006;143:139-49.